患者来源体外模型揭示甲状腺髓样癌微环境及酪氨酸激酶抑制剂耐药机制
本研究开发了一种两步法患者来源体外模型,先以多细胞球培养原代细胞,再转为贴壁培养。成功建立8株不同遗传背景的甲状腺髓样癌细胞系,可重现患者组织中的干细胞标志物变化,并在斑马鱼模型中显示血管生成和侵袭特性。药物筛选显示该模型可用于研究患者特异性药物反应,为临床前药测和机制研究提供平台。
要点
- 两步法培养可建立保持高可塑性的甲状腺髓样癌原代细胞系。
- 模型重现患者组织中干细胞/祖细胞标志物的变化。
- 药物筛选可识别影响酪氨酸激酶抑制剂敏感性的候选调节因子。
核心结论
- 两步法成功建立甲状腺髓样癌原代细胞系,保持高可塑性并重现患者组织异质性。
- 该模型为临床前药物测试和微环境相互作用研究提供平台。
研究设计与样本
- 研究采用两步法:先以多细胞球培养原代细胞,再转为贴壁培养。
- 通过靶向下一代测序评估遗传背景,并检测干细胞/祖细胞标志物、分泌功能、药物反应、体内外侵袭和血管生成能力。
主要发现
- 建立了8株不同遗传背景的甲状腺髓样癌患者来源细胞系。
- 培养物重现了患者组织样本中干细胞和祖细胞标志物的变化。
- 细胞系可在斑马鱼模型中成功异种移植,显示血管生成和侵袭特性。
- 药物筛选鉴定出对当前甲状腺髓样癌治疗敏感性的不同候选调节因子。
临床怎么用
- 该模型可用于患者特异性药物反应研究和临床前药物测试。
- 模型有助于探索肿瘤微环境相互作用和个性化治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy with a 10-year mortality rate up to 50%. Current therapies for metastatic MTC comprise various tyrosine-kinase inhibitors, but resistance often appears due to the need for lifelong treatments. Like in other tumors, genetic, epigenetic, post-transcriptional, post-translational, and cell-cell interaction events influence drug response. However, progress in understanding MTC biology is limited by the lack of reliable in vivo and in vitro models. This study aims to develop a patient-derived model faithfully reproducing the microenvironmental alterations present in MTC. METHODS: We applied a two-step protocol consisting of a first phase in which primary cells are cultivated as multicellular spheroids and a second phase in which they are switched to adherent cultures. After evaluation of the genetic background by targeted Next Generation Sequencing, we characterized our cells phenotype by examining a panel of stem/progenitor-related markers, the secretory abilities by ELISAs, the drug response by proliferation assays, the in vivo angiogenic and invasiveness by the use of zebrafish model, the in vitro invasivity by Matrigel Dome assays and the spatial variation of stem/progenitor marker in both 3D cell models and tissue samples by confocal microscopy. RESULTS: Our model allowed the establishment of eight MTC patient-derived cell lines with different genetic backgrounds. The cultures faithfully reproduced the changes in stem and progenitor markers that we detected in our cohort of MTC tissue samples and could be successfully xenotransplanted in zebrafish model, showing both angiogenetic and invasive properties. Drug screening assays revealed the potential of our model for the study of patient-specific responses, as we were able to identify different candidate regulators of the sensitivity to currently available therapies for MTC. CONCLUSIONS: Our two-step protocol successfully generated primary MTC lines that maintain high plasticity, can be cultivated for several passages, and recreate the heterogeneity observed in patients' tissues. Our model will offer a robust platform for preclinical drug testing and mechanistic studies, addressing a longstanding gap in MTC research. It enables exploration of tumor microenvironment interactions and personalized therapeutic responses, supporting progress beyond current genomic-driven frameworks.
引用
- Grassi ES, Ghiandai V, Gaudenzi G, et al. Patient-Derived in Vitro Models Reveal Insights into Medullary Thyroid Cancer Microenvironment and Resistance to Tyrosine Kinase Inhibitors. Thyroid. 2026. PMID: 41649007. doi:10.1177/10507256251408825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。